Hybribio Biotech reports Q1-Q3 2025 impairments, pledges assets for loan

Guangdong Hybribio Biotech has approved provisions for credit and asset impairment totaling RMB 89,770,782.84 for the first three quarters of 2025. This includes RMB 79,333,119.27 for credit impairment losses, primarily from accounts receivable and other receivables, and RMB 10,437,663.57 for asset impairment losses, mainly from inventory and fixed assets. The impairment provisions will reduce the company's total profit by RMB 89,770,782.84 for the period.

Concurrently, the company announced the pledge of its land use rights and buildings for the production workshop at the Chaoshan Economic Development Experimental Zone, North High-Tech Industrial Park, under a syndicated loan for the Hybribio Medical Science Park project. This pledge, securing a maximum liability of RMB 57,441,600, was made with China Construction Bank, Agricultural Bank of China, and Bank of Communications, all branches in Chaozhou.

These financial adjustments coincide with a 20.38% decrease in operating revenue to RMB 485,871,698.54 and a net loss attributable to shareholders of RMB -127,683,325.23 for the first three quarters of 2025. The company attributes the decline to industry policy changes, HPV-DNA detection product procurement, and increased VAT on its diagnostic reagents.